Concord, United States
Comanche Biopharma, founded in 2020, is headquartered in the United States and operates primarily within the Biopharma, Biotechnology, and Pharmaceutical industries. Their mission, encapsulated in their slogan, "Our purpose is to make every pregnancy around the world safer," highlights their commitment to improving maternal health globally.
The company is at the forefront of developing an investigational siRNA medicine designed to treat preterm preeclampsia, a significant advancement aimed at ensuring safer pregnancies. Comanche Biopharma is driven by a vision to provide accessible, evidence-based, and affordable solutions for pregnancy-related complications.
Recently, the company secured a $75.00M in a Series B investment on 17 January 2024. This significant investment round drew high-profile investors including New Enterprise Associates, Atlas Venture, F-Prime Capital, GV, Lilly Asia Ventures, and Longview Ventures. Their interest underscores faith in Comanche Biopharma's potential impact on global maternal health.
Malama Health